Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs).

Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter CA, Reid TR.

Oncoimmunology. 2018 Jul 23;7(9):e1478648. doi: 10.1080/2162402X.2018.1478648. eCollection 2018. Review.

PMID:
30228948
2.

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

Oronsky B, Reid TR, Oronsky A, Caroen S, Carter CA, Cabrales P.

Oncotarget. 2018 May 4;9(34):23439-23442. doi: 10.18632/oncotarget.25211. eCollection 2018 May 4.

3.

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

Oronsky B, Goyal S, Kim MM, Cabrales P, Lybeck M, Caroen S, Oronsky N, Burbano E, Carter C, Oronsky A.

Transl Oncol. 2018 Jun;11(3):771-778. doi: 10.1016/j.tranon.2018.03.014. Epub 2018 Apr 23. Review.

4.

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.

Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E.

J Investig Med High Impact Case Rep. 2018 Mar 7;6:2324709618760080. doi: 10.1177/2324709618760080. eCollection 2018 Jan-Dec.

5.

A note on improved statistical approaches to account for pseudoprogression.

Abrouk N, Oronsky B, Caroen S, Ning S, Knox S, Peehl D.

Cancer Chemother Pharmacol. 2018 Mar;81(3):621-626. doi: 10.1007/s00280-018-3529-4. Epub 2018 Feb 5.

PMID:
29404682
6.

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.

Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, Reid TR, Carter CA.

Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20. Review.

7.

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report.

Brzezniak C, Oronsky B, Carter CA, Thilagar B, Caroen S, Zeman K.

Case Rep Oncol. 2017 Mar 17;10(1):252-257. doi: 10.1159/000464278. eCollection 2017 Jan-Apr.

8.

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report.

Oronsky N, Thilagar B, Ray CM, Caroen S, Lybeck MMC, Ferry L, Voves RA, Oronsky B.

Case Rep Oncol. 2017 Apr 6;10(1):325-327. doi: 10.1159/000470833. eCollection 2017 Jan-Apr.

9.

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome.

Brzezniak CE, Vietor N, Hogan PE, Oronsky B, Thilagar B, Ray CM, Caroen S, Lybeck M, Oronsky N, Carter CA.

Case Rep Oncol. 2017 Apr 6;10(1):321-324. doi: 10.1159/000467390. eCollection 2017 Jan-Apr.

10.

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

Brzezniak C, Oronsky B, Trepel J, Summers TA Jr, Cabrales P, Lee MJ, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck HE, Brown JF, Reid TR, Carter CA.

Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.

11.

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.

Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B.

Expert Rev Hematol. 2017 Jun;10(6):575-582. doi: 10.1080/17474086.2017.1324779. Epub 2017 May 22.

PMID:
28448172
12.

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA.

Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.

PMID:
27855386
13.

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA.

Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.

14.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C.

Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.

15.

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.

Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016.

16.

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.

Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003.

17.

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C.

Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

18.

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.

Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016 Jan-Apr.

19.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.

Case Rep Oncol. 2016 Jan 28;9(1):62-7. doi: 10.1159/000443725. eCollection 2016 Jan-Apr.

20.

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.

Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016 Jan-Apr.

21.

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J.

Case Rep Oncol. 2015 Oct 30;8(3):461-5. doi: 10.1159/000441775. eCollection 2015 Sep-Dec.

22.

Dysphonia after Bevacizumab Rechallenge: A Case Report.

Carter CA, Caroen SZ, Oronsky AL, Oronsky BT.

Case Rep Oncol. 2015 Oct 14;8(3):423-5. doi: 10.1159/000441122. eCollection 2015 Sep-Dec.

23.

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance.

Oronsky B, Carter CA, Reid TR, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P.

Neoplasia. 2015 Sep;17(9):716-722. doi: 10.1016/j.neo.2015.09.001. Review.

24.

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T.

Redox Biol. 2015 Aug;5:422. doi: 10.1016/j.redox.2015.09.035. Epub 2015 Dec 30.

25.

The war on cancer: a military perspective.

Oronsky B, Carter CA, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid T.

Front Oncol. 2015 Jan 26;4:387. doi: 10.3389/fonc.2014.00387. eCollection 2014. Review.

26.

Follow the ATP: tumor energy production: a perspective.

Oronsky BT, Oronsky N, Fanger GR, Parker CW, Caroen SZ, Lybeck M, Scicinski JJ.

Anticancer Agents Med Chem. 2014;14(9):1187-98. Review.

PMID:
25102360

Supplemental Content

Loading ...
Support Center